Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis
Clozapine has unique efficacy for symptoms in treatment-resistant schizophrenia; however, symptomatic remission is not necessary nor sufficient for functional improvement. No study has pooled the effect of clozapine on psychosocial function across clinical trials.
We conducted a systematic review and meta-analysis to compare the effects of clozapine with other antipsychotics on psychosocial function, and described the predictors of functional outcome.
We searched MEDLINE/PubMed, PsychINFO, EMBASE, CINAHL, Scopus, Web of Science, Cochrane Central Register of controlled trials and clinical trial registries till April 2018, with no language limits. Eligible studies were randomised controlled trials of clozapine vs. typical or atypical antipsychotics among adults with treatment-resistant schizophrenia. We included studies with flexible or fixed doses of antipsychotics within the therapeutic range to reflect naturalistic care. Effect sizes of studies were pooled using generic inverse variance and random-effects models and presented as standard mean differences. Study quality was assessed in accordance with the Cochrane Collaboration guideline, and subgroup analyses were carried out to identify potential moderators and methodological biases.
Nine studies with 1279 participants (69.7% male) were included. Clozapine showed beneficial effects on psychosocial function, but both short-term trials [n = 3; comparing 99 people taking clozapine with 97 controls (standardised mean difference = 0.04; 95% confidence interval − 0.24, 0.32; p = 0.77; I2 = 0%)] and long-term trials [n = 5; comparing 415 people taking clozapine with 427 controls (standardised mean difference = 0.05; 95% confidence interval − 0.16, 0.27; p = 0.64; I2 = 50%)] showed no superiority of clozapine to other antipsychotics in this regard. Only one study explored the predictors of psychosocial function. Baseline severity of illness, illicit drug use, extrapyramidal side effects, sex and cognition explained the variability in functional outcome. A range of scales measured psychosocial function, and the quality of reporting varied across trials.
Clozapine does not appear superior to other antipsychotics for improvement of psychosocial function. Standardisation of psychosocial function measurement is needed to improve the quality of evidence. Further exploration of the predictors of good psychosocial outcomes with clozapine treatment may improve personalisation of care.
We are grateful to Emerita Prof. S. M. Essock and Prof. Will Carpenter for providing additional information on their published works. We also thank Suzanne Edwards for providing statistical support and advice.
Compliance with Ethical Standards
Andrew T. Olagunju is supported by an Australian Government Research Training Program Scholarship. Scott R. Clark has received a grant from the Lundbeck Institute outside the submitted work. Bernhard T. Baune has received a Grant from the National Health and Medical Research Council, Australia outside the submitted work.
Conflict of interest
Andrew T. Olagunju, Scott R. Clark and Bernhard T. Baune have no conflicts of interest directly relevant to the contents of this article.
- 4.GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1260–344.Google Scholar
- 5.GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.Google Scholar
- 8.Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009;1:CD000059.Google Scholar
- 13.Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess. 2006;10(17):iii–iv (ix–xi, 1–165).PubMedGoogle Scholar
- 17.Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3. Update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16(3):142–70.PubMedGoogle Scholar
- 28.Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;11:CD006633.Google Scholar
- 31.National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update). 2009. http://www.nice.org.uk/Guidance/CG82/NiceGuidance/pdf/English. Accessed 20 Apr 2009.
- 47.Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9 (W64).Google Scholar
- 48.Higgins JPTGS, editor. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. London: The Cochrane Collaboration; 2011.Google Scholar
- 54.StataCorp. Stata statistical software: release 15. College Station: StataCorp LLC; 2017.Google Scholar
- 58.Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Meta-regression, in introduction to meta-analysis. Chichester: Wiley; 2009.Google Scholar
- 60.Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997;337(12):809–15.PubMedGoogle Scholar
- 61.Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kühn KU, Bender S, Bandelow B, Lemmer W, Moritz S, Dittmann RW. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand. 2005;111(2):106–15.PubMedGoogle Scholar
- 64.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Text revised. 4th ed. Washington, DC: American Psychiatric Association; 2000.Google Scholar
- 69.EuroQoL. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.Google Scholar
- 86.Ranasinghe I, Sin J. A systematic review of evidence-based treatment for individuals with treatment-resistant schizophrenia and a suboptimal response to clozapine monotherapy. Psychosis. 2014;6(3):253–65.Google Scholar
- 88.Institute of Medicine. Psychosocial interventions for mental and substance use disorders: a framework for establishing evidence-based standards. In: Mary Jane E, Adrienne Stith B, Monica LG, editors. Closing the quality chasm: a proposed framework for improving the quality and delivery of psychosocial interventions, Chapter 2. Washington, DC: The National Academies Press; 2015.Google Scholar